소양증 치료제 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 질병 유형별, 제품별, 지역별, 부문별 예측(2024-2032년)

The global Pruritus Therapeutics market size is expected to reach USD 13.2 Billion by 2032, according to a new study by Polaris Market Research. The report "Pruritus Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Allergic Contact Dermatitis, Atopic Dermatitis, Urticaria, Others); By Product; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market for treating pruritus is seeing significant growth as a result of the increasing prevalence of chronic itching linked to various skin and systemic conditions. The growing awareness of pruritus's substantial impact on patient's quality of life is boosting the demand for effective treatment options. Advances in pharmaceuticals, particularly the creation of new biologics and targeted therapies, are broadening the range of treatments available for pruritus, leading to better patient outcomes. Additionally, the aging global population, which is more prone to conditions causing persistent itching, is further propelling market growth.

Key trends in the market include the development and use of biological drugs and immunomodulators that specifically target the molecular mechanisms underlying pruritus. The incorporation of advanced drug delivery systems to improve the effectiveness and adherence of topical treatments is also gaining momentum.

The rising incidence of dermatological disorders is a key driver for the pruritus therapeutics market. These conditions often manifest as chronic itching, significantly impacting patients' quality of life. Factors such as urbanization, pollution, and lifestyle changes contribute to the increasing global prevalence of skin diseases like eczema, psoriasis, and atopic dermatitis, resulting in compromised skin barriers and immune system changes. Furthermore, intense competition among major pharmaceutical companies and emerging biotech firms characterize the competitive landscape of the pruritus therapeutics market. These industry leaders are leveraging advanced biologics, immunomodulators, and targeted therapies to develop innovative treatments that address the root causes of pruritus.

Pruritus Therapeutics Market Report Highlights

The global market for pruritus therapeutics in 2023 was primarily driven by the atopic dermatitis segment, owing to the condition's high prevalence and chronicity. This condition is often characterized by severe and persistent itching as a primary symptom.

The corticosteroids segment had the highest revenue share in the pruritus therapeutics market in 2023. This was primarily due to their extensive utilization and established effectiveness in treating various inflammatory skin conditions that result in pruritus.

In 2023, North America established itself as the leading region in the global market due to its high prevalence of dermatological conditions like atopic dermatitis, psoriasis, and eczema. These conditions have significantly boosted the demand for pruritus treatments in the region.

The global key market players include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb, Cara Therapeutics, GSK plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., among others.

Polaris Market Research has segmented the pruritus therapeutics market report based on disease type, product, and region:

Pruritus Therapeutics, Disease Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Allergic Contact Dermatitis
• Atopic Dermatitis
• Urticaria
• Othersc

Pruritus Therapeutics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

• Antihistamines
• Calcineurin Inhibitors
• Corticosteroids
• Counterirritants
• Immunosuppressant
• Local Anesthetics
• Others

Pruritus Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of APAC
• Latin America
• Argentina
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of MEA

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Pruritus Therapeutics Market Insights

• 4.1. Pruritus Therapeutics Market - Industry Snapshot
• 4.2. Pruritus Therapeutics Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Prevalence of Dermatological Conditions
    • 4.2.1.2. Advances in Biotechnology and Pharmacology
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Adverse Effects and Safety Concerns
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Pruritus Therapeutics Industry trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Pruritus Therapeutics Market, by Disease Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Pruritus Therapeutics, by Disease Type, 2019-2032 (USD Billion)
• 5.3. Allergic Contact Dermatitis
  • 5.3.1. Global Pruritus Therapeutics Market, by Allergic Contact Dermatitis, by Region, 2019-2032 (USD Billion)
• 5.4. Atopic Dermatitis
  • 5.4.1. Global Pruritus Therapeutics Market, by Atopic Dermatitis, by Region, 2019-2032 (USD Billion)
• 5.5. Urticaria
  • 5.5.1. Global Pruritus Therapeutics Market, by Urticaria, by Region, 2019-2032 (USD Billion)
• 5.6. Others
  • 5.6.1. Global Pruritus Therapeutics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Pruritus Therapeutics Market, by Product

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
• 6.3. Antihistamines
  • 6.3.1. Global Pruritus Therapeutics Market, by Antihistamines, by Region, 2019-2032 (USD Billion)
• 6.4. Calcineurin Inhibitors
  • 6.4.1. Global Pruritus Therapeutics Market, by Calcineurin Inhibitors, by Region, 2019-2032 (USD Billion)
• 6.5. Corticosteroids
  • 6.5.1. Global Pruritus Therapeutics Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
• 6.6. Counterirritants
  • 6.6.1. Global Pruritus Therapeutics Market, by Counterirritants, by Region, 2019-2032 (USD Billion)
• 6.7. Immunosuppressant
  • 6.7.1. Global Pruritus Therapeutics Market, by Immunosuppressant, by Region, 2019-2032 (USD Billion)
• 6.8. Local Anesthetics
  • 6.8.1. Global Pruritus Therapeutics Market, by Local Anesthetics, by Region, 2019-2032 (USD Billion)
• 6.9. Others
  • 6.9.1. Global Pruritus Therapeutics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Pruritus Therapeutics Market, by Geography

• 7.1. Key findings
• 7.2. Introduction
  • 7.2.1. Pruritus Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
• 7.3. Pruritus Therapeutics Market - North America
  • 7.3.1. North America: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.3.2. North America: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.3.3. Pruritus Therapeutics Market - U.S.
    • 7.3.3.1. U.S.: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.3.2. U.S.: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.3.4. Pruritus Therapeutics Market - Canada
    • 7.3.4.1. Canada: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.4.2. Canada: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
• 7.4. Pruritus Therapeutics Market - Europe
  • 7.4.1. Europe: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.2. Europe: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4.3. Pruritus Therapeutics Market - UK
    • 7.4.3.1. UK: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.3.2. UK: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4.4. Pruritus Therapeutics Market - France
    • 7.4.4.1. France: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.4.2. France: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4.5. Pruritus Therapeutics Market - Germany
    • 7.4.5.1. Germany: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.5.2. Germany: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4.6. Pruritus Therapeutics Market - Italy
    • 7.4.6.1. Italy: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.6.2. Italy: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4.7. Pruritus Therapeutics Market - Spain
    • 7.4.7.1. Spain: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.7.2. Spain: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4.8. Pruritus Therapeutics Market - Netherlands
    • 7.4.8.1. Netherlands: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.8.2. Netherlands: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4.9. Pruritus Therapeutics Market - Russia
    • 7.4.9.1. Russia: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.9.2. Russia: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
• 7.5. Pruritus Therapeutics Market - Asia Pacific
  • 7.5.1. Asia Pacific: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.5.2. Asia Pacific: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5.3. Pruritus Therapeutics Market - China
    • 7.5.3.1. China: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.3.2. China: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5.4. Pruritus Therapeutics Market - India
    • 7.5.4.1. India: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.4.2. India: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5.5. Pruritus Therapeutics Market - Malaysia
    • 7.5.5.1. Malaysia: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.5.2. Malaysia: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5.6. Pruritus Therapeutics Market - Japan
    • 7.5.6.1. Japan: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.6.2. Japan: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5.7. Pruritus Therapeutics Market - Indonesia
    • 7.5.7.1. Indonesia: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.7.2. Indonesia: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5.8. Pruritus Therapeutics Market - South Korea
    • 7.5.8.1. South Korea: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.8.2. South Korea: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
• 7.6. Pruritus Therapeutics Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.6.2. Middle East & Africa: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.6.3. Pruritus Therapeutics Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.3.2. Saudi Arabia: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.6.4. Pruritus Therapeutics Market - UAE
    • 7.6.4.1. UAE: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.4.2. UAE: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.6.5. Pruritus Therapeutics Market - Israel
    • 7.6.5.1. Israel: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.5.2. Israel: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.6.6. Pruritus Therapeutics Market - South Africa
    • 7.6.6.1. South Africa: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.6.2. South Africa: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
• 7.7. Pruritus Therapeutics Market - Latin America
  • 7.7.1. Latin America: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 7.7.2. Latin America: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.7.3. Pruritus Therapeutics Market - Mexico
    • 7.7.3.1. Mexico: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.3.2. Mexico: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.7.4. Pruritus Therapeutics Market - Brazil
    • 7.7.4.1. Brazil: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.4.2. Brazil: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.7.5. Pruritus Therapeutics Market - Argentina
    • 7.7.5.1. Argentina: Pruritus Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.5.2. Argentina: Pruritus Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. AbbVie Inc
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Amgen Inc
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Astellas Pharma Inc
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Bristol Myers Squibb
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Cara Therapeutics
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. GSK plc
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. Novartis AG
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. Pfizer Inc
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. Sanofi
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Teva Pharmaceutical Industries Ltd
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development
• 9.11. Viatris Inc
  • 9.11.1. Company Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Development